Merck Life Sciences Acquires HUB Organoids
The Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the closing of the transaction to acquire HUB Organoids Holding B.V. (HUB) following regulatory clearances and the fulfilment of other customary closing conditions. The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for more faster and more effective drug development. Terms of the deal were not disclosed.
“The use of organoids offers tremendous potential to improve the drug discovery process,” said Jean-Charles Wirth, Head of Science & Lab Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany. “HUB’s advanced technology, combined with our cell culture expertise and broad portfolio, makes us a valuable resource for researchers looking to leverage the power of 3D cell culture to understand the impact of drug response earlier in the development process.”
HUB possesses the foundational patent portfolio on organoids and a robust service offering ranging from new model generation to assay development and high-throughput screening, enhancing Merck KGaA, Darmstadt, Germany´s offering of cell culture tools to academia, biotech, and pharma customers. The team of approximately 70 employees is celebrating the acquisition together at the HUB campus in Utrecht, Netherlands.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Free Bicycle Light Repairs Mark Launch of National Cycling Visibility Campaign in Utrecht
The national bicycle lighting campaign ‘AAN in het donker’ (Lights On in the Dark) will be launched on 29 October on Leuvenlaan at Utrecht Science Park. Between 5:00 p.m. and 7:30 p.m., cyclists can have their lights checked and repaired free of charge. André van Schie, Member of the Provincial Executive, will be there to talk to Utrecht residents about the importance of proper bicycle lighting.
Utrecht University and UMC Utrecht awarded with twelve NWO Vidi-grants
The Dutch Research Council (NWO) has awarded Vidi grants to 109 researchers. Twelve leading researchers at Utrecht University and UMC Utrecht will each receive a Vidi grant of up to €850,000. NWO awards Vidi grants annually, enabling recipients to develop an innovative line of research over the next five years and further expand their research teams.
ReVoice restores one’s own voice after voice loss
People who lose their voice, for example after surgery for head and neck cancer, want to be able to speak again with a voice that sounds like their own. ReVoice aims to provide this, with the help of AI. With this innovation, head and neck surgeon Weibel Braunius, innovation manager Mart Schoondermark, and patient Boudewijn Faber won the Ureka Mega Challenge 2026 from UMC Utrecht.
Looking back at Utrecht Science Week: research, education, and entrepreneurship in the spotlight
Utrecht Science Week 2026 has come to a close. For over a week, visitors enjoyed workshops, lectures, group discussions, and tours focused on science and innovation at Utrecht Science Park. With more than thirty program activities across over 25 locations, there were ample opportunities to experience science up close. We look back on a fantastic week that once again highlighted the essential role of collaboration, and the combination of research, education, and entrepreneurship, in addressing the societal challenges of our time.